According to GlaxoSmithKline PLC, a study shows its human papillomavirus vaccine, Cervarix, was effective against the types of HPV that are most likely to cause cervical cancer, but also fought other strains of the disease. A study of 18,644 women between 15 and 25 years, from 14 countries across Europe, Asia-Pacific and Latin and North America, showed significant protection against pre-cancerous lesions not containing the two most common virus types. Those receiving all three doses, the vaccine provided 92.9 percent protection. Results of the study were published in the Lancet.